Q-omics provides the consensus-scored NFYC-AS1 profile across patient tissues and cancer cell-line models. NFYC-AS1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NFYC-AS1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NFYC-AS1 RNA expression shows 20,070 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, COAD, and ACC as cancer lineages where NFYC-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFYC-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFYC-AS1 survival associations across molecular data types. NFYC-AS1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFYC-AS1 RNA expression–survival associations across cancer types. High NFYC-AS1 expression shows unfavorable associations in KIRC, LGG, ACC, UVM and UCEC, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NFYC-AS1 RNA expression.
This table summarizes NFYC-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NFYC-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFYC-AS1 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, CHOL, LIHC and READ. The COAD box plot shows higher NFYC-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.747, t-test p < 0.001).
This table shows molecular features associated with NFYC-AS1 in patient tissues and cancer cell lines. In patient samples, NFYC-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
